cAMPfield Phase 3 Psoriasis Trial Shows Prifemilast Efficacy

Prifemilast, an oral PDE4 inhibitor developed by cAMPfield Therapeutics, demonstrated superior efficacy compared to apremilast in a head-to-head Phase 3 plaque psoriasis trial presented on Friday, October 9, 2026, at the Fall Clinical Dermatology Conference.

### Money Play No specific investable tickers or vehicles are mentioned in the verified source facts for this clinical data release. Traders watching the broader specialty pharma sector should monitor pipeline execution milestones independently.

## Catalyst Analysis: Head-to-Head Phase 3 Results In the primary efficacy evaluation, prifemilast administered at 20 mg once daily nearly doubled the PASI 75 response rate compared to apremilast 30 mg twice daily, posting a 64.6% to 35.3% advantage. Co-primary endpoints also showed clear or almost clear skin achieved in 55.6% of patients on prifemilast versus 31.3% on the comparator arm. Serious adverse event rates remained low at 4.0% against 2.5%, with discontinuation rates comparable across cohorts.

## Technical Analysis & Key Risk Watch

96.94 · R1 ## Technical Analysis & Key Risk Watch 96.51 · last ## Technical Analysis & Key Risk Watch 96.27 · S1 ## Technical Analysis & Key Risk Watch 95.05 · S2 ## Technical Analysis & Key Risk Watch 90.97.

Trial results also underscored durability through a second placebo-controlled Phase 3 study extending to 52 weeks, with responses appearing as early as Week 2. With over 1,000 total participants dosed in the program, safety metrics remain central as cAMPfield advances the compound into global Phase 2 trials for ulcerative colitis and Crohn's disease.

## Impact on Sector Tenders The robust performance of a preferential PDE4 inhibitor in immune-mediated inflammatory pathways validates broader therapeutic expansion into overlapping gastrointestinal indications, shifting competitive dynamics for oral immunology assets.